Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
CYP17 polymorphism may influence tamoxifen-induced hepatic steatosis
February 16th, 2006
According to a study from Japan, cytochrome P450c17 alpha (CYP17) gene polymorphism may influence tamoxifen-induced hepatic steatosis. "Hepatic steatosis is a frequent complication, which sometimes develops nonalcoholic steatohepatitis (NASH), in breast cancer patients treated with tamoxifen, a potent antagonist of estrogen." "Recently we reported the impairment of fatty acid beta-oxidation and the enhancing fatty infiltration to hepatocytes in aromatase deficiency (ArKO) mice as the estrogen deficiency models. This experimental observation let us speculate a strong link between estrogen and hepatic steatosis," wrote T. Ohnishi and colleagues, Kochi...
Source: Women's Health Weekly (2006-02-16)
|
